Low body weight and type of protease inhibitor predict discontinuation and treatment‐limiting adverse drug reactions among HIV‐infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort

Ole Kirk(University of Copenhagen), Jens Lundgren(Centre of Excellence for Health, Immunity and Infections), Niels Obel(University of Copenhagen), Terese L. Katzenstein, L Mathiesen, C. Pedersen, Jan Gerstoft, Henrik Nielsen(Aalborg University Hospital)
HIV Medicine
January 1, 2001
10.1046/j.1468-1293.2001.00045.x
Cited by 17

Related Papers

Industrial enzyme applications
|Current Opinion in Biotechnology|2002|1.5k
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
|The Lancet|2003|1.2k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
|AIDS|2003|987